INTRODUCTION

Stereotactic ablative body radiotherapy (SABR) uses hypofractionated dose schedules (3– to 8 fractions) and high precision treatment delivery to improve local control of disease. The radiobiological rationale for hypofractionation: that delivery of a few large fractions over a short overall treatment time will achieve a greater therapeutic ratio than delivery of standard treatment regimens of 20 or more fractions, is indicated in numerous studies for a range of clinical indications.¹⁻³

However, there are significant challenges associated with introducing SABR into the clinic due to the high dose fractions, the non-standard method of dose prescription and the complex nature of both planning and delivery.⁶⁻⁷

The UK SABR Consortium was established in 2008 with the aim of achieving a consensus on how best to develop, implement and research SABR in the UK. The UK SABR Consortium guidelines,⁸ which are intended to standardise UK implementation and ensure safe delivery of SABR were originally written for early stage lesions in the peripheral lung, however this guidance has been updated and significantly re-structured and covers the application of SABR for other primary tumours and oligo-metastatic disease. The most recent version is available online (https://www.sabr.org.uk/wp-content/uploads/2019/04/SABRconsortium-guidelines-2019-v6.1.0.pdf).

In the UK, the 2011 National Radiotherapy Implementation Group (NRIG) report (SBRT: Guidelines for Commissioners, Providers and Clinicians in England 2011),⁹ recommended that SABR had become a standard of care for the management of early stage medically inoperable peripheral non-small-cell lung carcinoma.
In 2012 a comprehensive survey\textsuperscript{10} was led by the Consortium to quantify the number of UK centres actively treating with SABR and the number intending to develop a SABR service in the next 2 years, obtain details of current practice, identify current and future clinical sites being treated with SABR, identify the equipment used in different institutions to match centres starting up, quantify the resource implications of a SABR service, determine if Consortium guidelines\textsuperscript{8} are being adhered to, guide best practice and alert outlying centres to possible improvements in workflow and quality.

Over the last 6 years, there have been several key developments both in terms of technology and infrastructure. These include:

1. Funding from NHS England for a mentorship scheme that supported three centres in developing and introducing a lung SABR service
2. In 2013 the NHS Commissioning Board (NHS CB) agreed to commission Stereotactic Body Radiotherapy/Stereotactic Radiosurgery for patients with early non-small cell lung cancer\textsuperscript{11, 12} and cerebral metastasis.\textsuperscript{12}
3. A national dosimetry audit for Lung SABR was developed and conducted in 24 centres.\textsuperscript{13} This audit is now used by the Radiotherapy Trials Quality Assurance (RTTQA) group as a pre-requisite for clinical trials
4. In 2015 NHS England’s Commissioning through Evaluation (CtE) programme\textsuperscript{14, 15} enabled 17 centres to start treating a limited number of patients with SABR for oligometastatic disease, re-irradiation of the pelvis and spine and hepatocellular carcinoma.
5. The development of national portfolio of SABR research studies to investigate the utility of SABR in the treatment of oligometastatic disease, primary lung, prostate, pancreas and hepatobiliary malignancies.\textsuperscript{16–20}

Therefore, it was considered timely to conduct a second survey to update results from 2012\textsuperscript{10, 21} and see how the SABR landscape in the UK has evolved. The aim was to ascertain the progress being made in the implementation of SABR treatment, obtain details of current practice in centres with an active treatment programme and identify barriers to implementation/progress. Any issues highlighted by the survey could then be addressed within the NHS to improve access to SABR services and trials in the UK.

METHODS AND MATERIALS

An online questionnaire was sent to the Consortium membership to identify a local SABR Lead at 65 UK radiotherapy centres in January 2018. The survey consisted of 72 questions and was divided into 5 sections to allow completion by different relevant staff groups (see suppl 1). Non-responders were followed up by an email to the Head of Physics in April, which increased the final response rate to 77% (50/65 UK institutions).

The questionnaire (updated since 2012, to reflect advancements in technology and current service provision) covered several areas, often in considerable detail: current and intended number of patients being treated for each clinical site; immobilization and motion management methods; CT scanning protocols; target and OAR delineation; treatment planning; image-guidance and treatment protocols; QA methods.

Amongst “treating” centres the response rate to some questions was partial due to the wide scope of the questionnaire. Results are therefore quoted as a fraction with the denominator indicating the number of the centres responding to each question. Centres that reported that they were not currently treating SABR were only included in analysis relating to questions on four-dimensional CT (4DCT) scanning experience, barriers to implementation and future plans. In contrast to 2012, data for intracranial SRS/T have been collected as one of the non-lung SABR sites for oligometastatic disease. Results from this survey have been compared to those from 2012,\textsuperscript{10} and to national and international guidelines/recommendations including UK SABR Consortium,\textsuperscript{8} ESTRO ACROP,\textsuperscript{22} AAPM,\textsuperscript{23} Australian and New Zealand\textsuperscript{24} and EORTC.\textsuperscript{25, 26}

RESULTS

Current status and future expectations of UK SABR provision

50/65 (77%) centres responded to the questionnaire. The number of centres with an active SABR program has greatly increased since 2012, 38/50 (76%) vs 15/48 (31%) responding centres, with a further 12/50 responding centres planning to start SABR in the next two years. Intracranial SRS/T data were not collected in 2012.

SABR for Lung cancer—Centres treating primary peripheral lung cancers have more than doubled since 2012 (15/48–35/50, Figure 1), in line with the intentions we documented in 2012. The number of patients with peripheral non-small-cell lung carcinoma treated by each centre per annum varied from 1 to 10 to over 200 (range described in Table 1). 26/35 (74%) of responding centres are treating more than 25 patients per annum, the minimum level of provision recommended by NRIG.\textsuperscript{9}

The number of patients treated per annum from all centres has increased from 458 in 2012 to 1676 (Table 2). 12/35 centres are also treating central lung tumours.

SABR for other primary sites—30/50 (60%) responding centres deliver SABR to non-lung sites with intracranial (20 centres) and prostate (18 centres) being most common sites. Centres treating prostate and primary hepatic tumours have increased by six and two-fold respectively.

SABR for oligo-metastatic disease—27/50 (54%) responding centres are offering SABR to the range of sites required for treating oligo-metastatic disease. This has significantly increased since 2012 where the number of patients treated per annum has increased from 144 to 984 (Table 2).

Barriers in implementing a SABR service

The response to this question allowed centres to tick multiple options/barriers (based on previous survey) with additional free text to detail specific challenges. While lack of NHS contracts continues to be a barrier for the non-SABR centres there are...
other challenges including lack of staff, equipment, training to existing staff, machine time on linacs, MRI capacity and lack of resources that have been highlighted as impacting on expanding SABR service in treating centres.

For peripheral lung SABR, 8/46 (17%) responding centres indicated they had problems with obtaining an NHS contract and three centres highlighted loss of an existing contract despite having the expertise. 9/42 (21%) responding centres indicated lack of training to existing staff as challenges. Other challenges documented were lack of machine time on linacs (12/42 (29%) with 22/42 (52%) of responding centres raising other issues including specific technical challenges with motion management and lack of MRI capacity.

A major concern is that for SABR to oligometastatic disease, intracranial SRS/T and implementation of/recruitment into SABR trials: lack of funding/NHS contract seems to be the major barrier as indicated by 13/19 (68%), 21/42 (50%) and 21/41 (51%) of responding centres respectively.

33/50 (66%) responding centres are currently referring to a different centre for SABR to various sites. Inequity in terms of geography has been highlighted by four centres where patients suitable for SABR refuse to travel and thereby are deprived of the service.

Managing tumour motion and CT simulation

Immobilization and management of tumour motion is essential to accurately deliver a high dose to the target. A range of immobilization devices are used throughout the UK, as in Figure 2. In summary, it is worth noting that established practice mainly utilizes standard immobilization devices (±abdominal compression), with the stereotactic body frame only used by 2/37 (5%) responding centres.

Lung (Figure 3)—the wing board is used by 29/37 (78%) responding centres with several centres using a combination of devices, the most popular combination remains the use of a wingboard with vacuum immobilisation and knee support by 24/37 (65%) of responding centres. There is an increased use of abdominal compression from 2 to 10 centres. Other includes thermoplastic shells, BodyFix® (Medical Intelligence, Medizintechnik GmbH, Schwabmunchen, Germany) and mattresses.

Table 1: The number of patients with peripheral NSCLC treated by each centre per annum

| No of patients treated per annum | No of centres (% of 35 treating centres) |
|---------------------------------|----------------------------------------|
| 1–10                            | 5 (14%)                                |
| 11–25                           | 4 (11%)                                |
| 26–50                           | 9 (25%)                                |
| 51–75                           | 7 (20%)                                |
| 76–100                          | 2 (6%)                                 |
| 101–150                         | 2 (6%)                                 |
| 151–200                         | 3 (9%)                                 |
| 200–250                         | 3 (9%)                                 |

NSCLC, non-small-cell lung carcinoma.
Abdominal sites —>50% of centres treating liver, pancreas and adrenal indications have implemented abdominal compression with further centres expressing a future interest.

Amongst 45 responding centres, there is an even split with respect to CT manufacturers with Philips Healthcare (Best, Netherlands), GE Healthcare (Buckinghamshire, UK) and Toshiba (Canon Medical Systems, USA) each in 13 centres and Siemens Healthcare (Erlangen, Germany) in 12 centres (a couple of centres own more than one scanner). All 50 centres are using 4DCT for SABR or intend to use 4DCT once they have a SABR program with a maximum slice thickness of 3 mm. Only one centre is yet to implement 4DCT. 4DCT experience has increased nationally, with 24/35 (69%) responding SABR active centres having treated >100 patients compared to 4/17 (23%) in 2012, Figure 4.

Evaluation of tumour motion prior to 4DCT is no longer easily achievable with the demise of simulators. A couple of centres indicate the use of CBCT or fluoroscopy. Failure rate is low with most responding centres reporting <6% of scans not usable for motion assessment (lung—37/43 and abdomen—18/21) and remains primarily due to issues of patient compliance or breathing irregularity. 4DCT scans are assessed either qualitatively or quantitatively by 42/43 responding centres, with 34/35 (69%) responding SABR active centres making an assessment. Free text responses indicate that scans are still considered acceptable so long as the artefact is not in the region of interest.

In contrast to 2012, in combination with 4DCT we now see a wide variation of other scanning protocols (Figure 5). This is most likely a consequence of the development of linac-based SABR for treatment sites other than lung. This differs from 2012 when gating, breath-holding and abdominal compression were rarely used in UK SABR practice and is more in line with the US survey of SABR practice which suggests that 4DCT (used in 75% of centres) is often used in combination with abdominal compression (51%) or gating (31%). For example 12/17 (70%) responding centres indicate the use of 4DCT with abdominal compression for liver.

Figure 2. Immobilization devices currently used in the UK for SABR (38 treating centres). SABR, stereotactic ablative radiotherapy.

Table 2. Annual numbers of treated patients in 2018 compared to 2012 for (a) primary sites and (b) oligometastatic indications

| Primary Sites          | Intracranial | Lung peripheral | Lung central | Prostate | Renal | Pancreas | Head & Neck | Liver | Spine |
|------------------------|--------------|----------------|--------------|----------|-------|----------|-------------|-------|-------|
| 2012                   | n/a          | 458            | n/a          | 31       | 2     | 19       | 31          | 4     | 40    |
| 2018                   | 2176         | 1676           | 42           | 202      | 12    | 36       | 6           | 74    | 18    |

| Oligometastases        |              |                |              |          |       |          |             |       |       |
|------------------------|--------------|----------------|--------------|----------|-------|----------|-------------|-------|-------|
| 2012                   | 144          |                |              |          |       |          |             |       |       |
| 2018                   |              |                |              |          |       |          |             | 984   |       |
In lung, there appears to be a preference for imaging the entire scan volume, with 28/46 (61%) of all responding centres and 21/35 (60%) responding SABR active centres using this method. However, in the abdominal region there is an equal split between centres using full/partial scan lengths. Contrast is used by 28/33 (85%) responding centres (14/17 (82%) in 2012) as standard or in selected lung SABR cases. For liver, adrenal and pelvic node SABR, this is the case for >95% of responding centres (19/20, 16/16 and 18/19 respectively).

For prostate SABR 9/11 (82%) responding centres do not use contrast, with 2/11 (18%) responding centres using it only in selected patients.

Dose–length product (DLP) values to indicate the typical 4DCT scan dose were reported for 44 scans at 30 responding centres (17 partial and 27 full 4DCTs). For this analysis, partial scan data were excluded. This was due to variation in whether the DLP reported was for just the partial 4DCT scan within the scan protocol or if the reported DLP was for the complete scan protocol and included the three-dimensional CT (3DCT) required for treatment planning. Furthermore, data were not captured on the partial 4DCT scan length which would correlate with DLP.

Lung—DLP values were found to vary by almost an order of magnitude (range 626–3500). Similar findings were seen in 2012 (range 400–3840) and this also correlates with a recent dose audit completed by IPEM on radiotherapy planning scans.28 There is a large dependence on manufacturer, with the Phillip's and Toshiba scanner tending to yield the lowest DLP and GE the highest. IPEM reported similar findings with Philips and GE scanners, but conversely they found Toshiba yielded the highest DLP along with GE. The difference is most likely due to the very small sample size of Toshiba data in this survey.

Abdominal sites—5/30 responding centres reported DLP values for 7 full 4DCT scans. Similar to lung these were found to vary by an order of magnitude (range 750–7165) with Philips yielding the lowest DLP.

The manufacturer's dependence on DLP is likely to do with the different 4D-CT implementation used by different manufacturers, and this is also noted in the IPEM report.28 IPEM have proposed a planning scan dose reference level of 1750 mGy cm for Lung 4D scans. Data were not captured on the use of any dose reduction techniques, and this could also be adding to the large range of values.

Delineation

Lung—33/35 (94%) responding centres delineate an internal target volume (ITV) to contain respiratory-induced tumour motion within the treated region. There exists a wide variation in the methods used to create an ITV including: directly from...
the maximum intensity projection or from the union of gross tumour volumes (GTVs) on all or a selection of individual phases. The two centres only delineating a GTV on a selected phase include a CyberKnife™ (Accuray Inc., Sunnyvale, CA) centre and a centre always using abdominal compression or exhale breath-hold. Cyberknife centres use Cyberknife synchrony tracking motion management system and only use a small ITV where the target-surrogate relationship is not perfect for tracked treatments. Other approaches include a permutation of several of the above methods and one centre using the MidVentilation29 method.

Abdomen—For liver in particular, delineation of a GTV on a selected phase or ITV using a GTV from selection of individual phases is more common (Figure 6). This is most likely due to the increased use of breath-hold techniques and inability to accurately use a maximum intensity projection reconstruction for delineation in this region.

It is most common to have uniform PTV expansion margins, except in the prostate where a smaller posterior margin is used in line with the PACE trial18 and two centres using 6 mm and one centre 7 mm craniocaudally for lung. Reported PTV

Table 3. (a) Lung 4D-CT scan DLP values grouped by scanner manufacturer with 2012 values in (). (b) Abdominal 4DCT scan DLP values grouped by scanner manufacturer.

| Manufacturer                        | n   | DLP mean (mGy cm) | DLP range (mGy cm) |
|-------------------------------------|-----|-------------------|--------------------|
| (a)                                 |     |                   |                    |
| Philips Healthcare (Best, Netherlands) | 8 (4)| 963 (648)         | 626–1615 (400–800) |
| GE Healthcare (Buckinghamshire, UK)  | 6 (5)| 2321 (2756)       | 1000–3500 (1440–3840) |
| Siemens Healthcare (Erlangen, Germany) | 4 (2)| 1794 (1550)       | 800–2936 (1500–1600) |
| Toshiba (Canon Medical Systems, USA) | 2   | 996               | 732–1260           |
| (b)                                 |     |                   |                    |
| Philips Healthcare (Best, Netherlands) | 2   | 1350              | 750–1950           |
| GE Healthcare (Buckinghamshire, UK)  | 3   | 3717              | 987–7165           |
| Siemens Healthcare (Erlangen, Germany) | 2   | 1850              | 1850               |

4DCT, four-dimensional CT; DLP, dose–length product; IPEM, Institute of Physics and Engineering in Medicine.
Margins vary from 1 to 6 mm, with 5 mm being more common in treatment sites where there is uncertainty due to breathing motion, e.g. lung and liver lesions (Figure 7). This is in agreement with the minimum median CTV-to-PTV margin of 5 mm report in the ESTRO ACROP consensus guidelines. Three centres said that lymph node margins vary between 3 and 5 mm. Reasons given were tumour type, expected growth, location, motion and visibility of target. One centre reported that for bone SABR patients CTV expansion is variable 0–10 mm based on clinician judgement.

Figure 7. The PTV margin size across a number of treatment sites. PTV, planning target volume.
to delineate more complex OARs. Only 2/36 (6%) responding centres replied yes to radiologist input.

**Treatment planning**

For lung, 31/34 (91%) of responding centres are using VMAT compared with 50% in 2012 and all 34 responding centres are using inverse planning (70% in 2012), with only one centre also using forward planning.

At linac centres across all treatment sites, fixed-field IMRT is only used by two centres (but not exclusively) making VMAT by far the most popular delivery method. Five centres are still using non-coplanar beams only if there is an advantage.

All centres are now either using a Type B or Monte Carlo (MC) algorithm for Lung as recommend by national and European guidelines. However, CyberKnife centres are still using a Type A algorithm for other abdominal SABR sites. In contrast to 2012 when no centres reported the use of MC, there are now nine centres using MC (Accuray (5), Monaco (4)).

**Treatment and verification**

SABR treatments in the UK are delivered across a variety of platforms (Figure 9). 32/36 responding centres deliver SABR on conventional linear accelerators with CBCT imaging facilities.

An important development over the last 6 years is that SABR for extracranial sites like prostate, pancreas and renal is no longer performed exclusively in Cyberknife centres.

Centres were asked details of their treatment verification at Day0/1 and subsequent fractions. There is a wide range of
methods being used as evident in Figure 10 for lung. This picture is similar across other treatment sites. Image guidance is mainly with a soft tissue registration with some centres also using a preliminary automatic match to a region of interest around the PTV. Since 2012 we have seen the introduction of 4DCBT by 10/35 (29%) responding centres for lung. However, only 4 of these 10 centres have chosen to implement 4DCBCT for liver, and fewer for other sites. The use of ExacTrac stereoscopic imaging on the Novalis is reported by six centres for treating spinal tumours. 8/20 (40%) responding centres are using fiducial matching for prostate SABR but only 3/21 (14%) for liver. One centre reports the use of Surface Guided Technology using AlignRT from VisionRT Ltd (London, UK) on all SABR patients.

This wide range of verification methods are used in some combination several times per treatment according to each individual department’s protocol. Free text responses indicated that there exists a wide range of workflows among responding centres.

**Quality assurance**

The high dose per fraction used in SABR require increased accuracy both in terms of dose calculation and positioning of steep dose gradients, therefore rigorous QA is essential.8

20/36 (56%) responding centres perform additional machine QA, mainly involving tighter tolerances and the Winston-Lutz test. Across all treatment sites 35 responding centres said they are still performing patient specific QA. On average across all treatment sites > 50% of these 35 centres perform at least two methods—no change from 2012. For lung, the most frequently used method is Delta4, followed by Arc Check and chamber measurement. All 35 centres said that patient specific...
QA is performed by a member of the physics staff. In a few centres, other staff are also involved (radiographers 4, techni-
cians 2, dosimetrists 4). Across all treatment sites, a range of acceptance criteria were indicated dependent on equipment
used, local or global $\gamma$ and normalization. However, the most
frequently used acceptance criteria was a $\gamma$ index of 3%/3 mm
for two-dimensional and 3D image analysis and dose difference
of 3% for chamber measurements.

Timings for entire process of lung SABR
To help centres allow for the extra time resources required for
the implementation of a SABR technique and to allow comparison
amongst established centres, the questionnaire asked each
centre to state the time required for each major step in the SABR
workflow.

The length of 4DCT scan sessions, and planning time was seen
to increase (Table 4) since 2012 reflecting increased complexity
of cases and perhaps, the planning of multiple lesions for oligo-
metastatic disease. Although lung SABR treatment delivery is on
average quicker than for other sites, perhaps since this is the site
in which most experience has been gained.

In addition, in this survey beam-on time data were captured,
with a mode of $\leq 5$ min, indicating that the majority of treatment
delivery time is set-up and imaging. This deserves attention
both with respect to patient comfort and intrafraction motion.
The short beam-on times is most likely a reflection of the docu-
mented increased use of VMAT and perhaps increased imple-
mentation of FFF (not captured in the Survey).

Plans for implementation of new techniques
Centres were asked for details of new planning techniques or
equipment, new treatment and imaging techniques or equip-
ment that they plan to implement over the next two years. Free
text replies included implementation of 4D CBCT (nine centres),
10 FFF (seven centres), Raystation (Raysearch Laboratories SB,
Sweden) (five centres), Abdominal Compression (four centres),
Surface Guided Radiotherapy (four centres), MRI Linac (three
centres), Gating (three centres).

Table 4. Summary of the most frequent time at each stage of
the SABR process in the UK (’quicker if several plans batched
together)

|                      | Mode – 2012 (min) | Mode – 2018 (min) |
|----------------------|------------------|------------------|
| 4DCT                 | 30–40            | 50–60            |
| Target and OAR delineation | 30–60          | 30–60            |
| Treatment planning    | $>91$            | $>120$           |
| Patient-specific plan QA | 30–45          | 15–30            |
| Daily treatment delivery | 21–30          | Lung 21–30       |

|                      | Other 31–40      |

4DCT, four-dimensional CT; OAR, organ at risk; QA, quality assurance.

DISCUSSION
As in 2012, this survey has a high response rate (77%) indi-
cating that UK centres remain engaged with SABR and that the
survey provides an accurate reflection of current practice and
the aspirations of future provision of SABR in the UK. Hence
the survey adds robust data for SABR treatment across a range
of sites and not just peripheral lung as was the case in 2012. It
has been possible to assess how realistic the intentions expressed
in 2012 were and note if further investment is still required to
increase provision of this clinically advantageous technique.
Whilst the number of peripheral lung patients treated per annum
has increased (Table 1), it remains below the demand estimated
in the NRIG guidance for Commissioners. This is a concern
particularly as Dutch data suggest that to improve outcome
across a population SABR needs to be accessible and delivered at
all radiotherapy centres.

The emerging data for treatment of oligometastatic disease from
the SABR-COMET$^9$ and Gomez trial$^{31,32}$ suggest that there will
be a role for SABR going forward. The UK has an important role
in confirming these finding through our current portfolio of studies$^{16–18}$ and it is worrying that a number of centres report
significant challenges in contributing to these studies. Increasing
the support for radiotherapy trials needs to be a priority for the
NHS to ensure these important studies are completed so that we
have an evidence base that can lead to commissioning of an
appropriate level of SABR treatment for oligometastatic disease
once the current NHS program$^{14}$ is completed.

The other challenge is the rapid development and adoption of
innovative approaches (e.g. MR Linac) that are likely to impact
of the delivery of SABR treatment over the next 5–10 years.
These changes will require us to streamline our SABR education
and training and allow the necessary complex quality assurance
through the collaborative approach adopted by the UK SABR
Consortium and seen in the Australia and New Zealand SABR
service.$^4$

The survey also provides reassurance that SABR treatments in the
UK are largely performed according to UK SABR Consortium
Guidelines$^8$ and European recommendations/guidelines.$^{22,25}$
This is especially true with respect to immobilization and the
predominant use of 4DCT (mandated by ESTRO ACROP$^{22}$) with a
maximum slice thickness of 3 mm.

The recommended use of contrast by the Consortium$^8$ and
AAPM guidelines for the hepatic system is followed for liver
and adrenal sites by 19/20 and 16/16 responding centres respec-
tively. ESTRO ACROP consensus guidelines$^{22}$ report that for
lung the ITV concept for delineation as a mandatory minimum
and MidV as recommended and VMAT recommended for best
SBRT practice. Again, compliance is high with 94% (33/35) and
91% (31/34) of responding centres using an ITV and VMAT
approach respectively. Results indicate that centres are also
following advice in limiting non-coplanar beams together with
increased use of VMAT and flattening filter free (FFF) to keep
treatment times as short as possible and in so doing reducing
intrafraction motion.
Documented changes in practice since 2012 include the development of Linac delivered SABR to most non-lung sites, notable increase in number of centres using abdominal compression as part of the immobilisation process (14 vs 2 centres) and the introduction of 4DCBCT in the imaging verification process. Of the 10 centres using 4DCBCT, 8 are Elekta sites, which is most likely a reflection of Varian’s 4DCBCT solution until recently not being well integrated into an online workflow. EORTC recommend that 4DCBCT is preferable over 3DCBCT, and therefore the intention of 9 more centres to implement this technology is welcome. A wide range of approaches were noted in accounting for tumour motion, target ITV delineation and treatment image verification. Comparable results focussing specifically on Lung SABR image-guided radiotherapy were recently published by the Cancer Research UK Advanced Radiotherapy Technologies Network (ARTNET). 33

The fact that there appears to have been no notable reduction in patient specific QA is not surprising given the extensive use of VMAT. In the ESTRO ACROP guidelines 50% of institutions consider patient–individual QA of VMAT planning mandatory and 50% as recommended. 22 However, it is worth noting that the time spent per patient on QA is dropping suggesting improvements in process. An increase in time spent at some stages of the SABR process was also seen which is likely to be a reflection on the increased complexity of cases treated.

CONCLUSION

This 2018 survey shows a welcome increase in SABR provision across the UK, surpassing projections in 2012. However, with emerging data it is clear that the UK SABR program needs to continue its expansion to ensure that patients with oligometastatic disease have access and SABR for early stage lung is deliverable in all centres. Implementation of novel technology is noted, however, guidance to address variability in target delineation, image guidance and possible reduction in patient specific QA is warranted.

ACKNOWLEDGMENT

We would like to thank all the centres who contributed to the data collated by this questionnaire.

REFERENCES

1. Aitken KL, Hawkins MA. Stereotactic Body Radiotherapy for Liver Metastases. Clin Oncol 2015; 27: 307–15. doi: https://doi.org/10.1016/j.clon.2015.01.032

2. Franks KN, Jain P, Snee MP. Stereotactic Ablative Body Radiotherapy for Lung Cancer. Clin Oncol 2015; 27: 280–9. doi: https://doi.org/10.1016/j.clon.2015.01.006

3. Henderson DR, Tree AC, van As N. Stereotactic Body Radiotherapy for Prostate Cancer. Clin Oncol 2015; 27: 270–9. doi: https://doi.org/10.1016/j.clon.2015.01.011

4. Ball D, Mai GT, Vinod S, Babington S, Ruben J, Kron T, et al.; in press Stereotactic ablative radiotherapy versus standard radiotherapy in stage I non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial. Lancet Oncol 2019; 20: 494–503. doi: https://doi.org/10.1016/S1470-2045(18)30896-9

5. Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiat Oncol Biol Phys 2018; 102: S3–S4. doi: https://doi.org/10.1016/j.ijrobp.2018.06.105

6. Martin A, Gaya A. Stereotactic Body Radiotherapy: A Review. Clin Oncol 2010; 22: 157–72. doi: https://doi.org/10.1016/j.clon.2009.12.003

7. Jain P, Baker A, Distefano G, Scott AJD, Webster GJ, Hatton MQ. Stereotactic ablative radiotherapy in the UK: current status and developments. Br J Radiol 2013; 86: 20130331. doi: https://doi.org/10.1259/bjr.20130331

8. . Stereotactic Ablative Body Radiotherapy (SBRT): A Resource. 2019. Available from: https://www.sabr.org.uk/wp-content/uploads/2019/04/SABRconsortium-guidelines-2019-v6.1.0.pdf.

9. National Radiotherapy Implementation Group Report. SBRT Guidelines for Commissioners, Providers and Clinicians in England. London, UK; 2011.

10. Distefano G, Baker A, Scott AJ, Webster GJ. UK SABR Consortium Quality Assurance Group. Survey of stereotactic ablative body radiotherapy in the UK by the QA group on behalf of the UKSABR Consortium. Br J Radiol 2014; 87: 20130681: 20130681:. 11. NHS Commissioning Board Clinical Reference Group for Radiotherapy: Clinical Commissioning Policy: Stereotactic Ablative Body Radiotherapy for Non-SmallCell Lung Cancer (Adult). 2013. Available from: https://www.england.nhs.uk/commissioning/wp-content/uploads/sites/12/2013/08/b01-p-a.pdf.

12. Clinical Commissioning Policy Stereotactic Radiosurgery / Radiotherapy for Cerebral Metastases. 2013:Reference: NHS/CB/ D05/P/d.

13. Distefano G, Lee J, Jafari S, Gouldstone C, Baker C, Mayles H, et al. A national dosimetry audit for stereotactic ablative radiotherapy in lung. Radiother Oncol 2017; 122: 406–10. doi: https://doi.org/10.1016/j.radonc.2016.12.016

14. Director C. Specialised Services,. NHS England. Methods: Commissioning through Evaluation; 2017. https://www.england.nhs.uk/wp-content/uploads/2017/06/methods-commissioning-through-evaluation.pdf.

15. . Commissioning through Evaluation.. Available from: https://www.england.nhs.uk/commissioning/spec-services/npc-crg/comm-eval/

16. Conventional Care Versus Radioablution (Stereotactic Body Radiotherapy) for Extracranial Oligometastases (CORE. Clinical TrialsAvailable at.

17. Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer (SARON. Clinical TrialsAvailable at.

18. McDonald F. Hanna GG Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial Clinical Oncology 2018; 30: 1–4.

19. Prostate Advances in Comparative Evidence (PACE. Clinical TrialsAvailable at.

20. ABC-07 Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract. . Cancer Research UK.. Available from: http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-chemotherapy-stereotactic-radiotherapy-
people-locally-advanced-bile-duct-cancer-abc-07-undefined.

21. Jain P, Baker A, Distefano G, Scott AJD, Webster GJ, Hatton MQ. Stereotactic ablative radiotherapy in the UK: current status and developments. Br J Radiol 2013; 86: 1029. doi: https://doi.org/10.1259/bjr.20130331

22. Guckenberger M, Andratschke N, Dieckmann K, Hoogeman MS, Hoyer M, Hurkmans C, et al. ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer. Radiotherapy and Oncology 2017; 124: 11–17. doi: https://doi.org/10.1016/j.radonc.2017.06.003

23. Benedict SH, Yenice KM, Followill D, Galvin JM, Hinson W, Kavanagh B, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010; 37: 4078–101. doi: https://doi.org/10.1118/1.3438081

24. Foote M, Bailey M, Smith L, Siva S, Hegi-Johnson F, Seeley A, et al. Guidelines for safe practice of stereotactic body (ablative) radiation therapy. J Med Imaging Radiat Oncol 2013; 59: 646–53. doi: https://doi.org/10.1111/1754-9485.12336

25. De Ruyscher D, Faivre-Finn C, Nestle U, Hurkmans CW, Le Péchoux C, Price A, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol 2010; 28: 5301–10.

26. De Ruyscher D, Faivre-Finn C, Moeller D, Nestle U, Hurkmans CW, Le Péchoux C, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. Radiother Oncol 2017; 124: 1–10. doi: https://doi.org/10.1016/j.radonc.2017.06.003

27. Pan H, Simpson DR, Mell IK, Mundt AJ, Lawson JD. A survey of stereotactic body radiotherapy use in the United States. Cancer 2011; 117: 4566–72. doi: https://doi.org/10.1002/cncr.26067

28. Wood TJ, Davis AT, Earley J, Edyvean S, Findlay U, Lindsay R, et al. IPEM topical report: the first UK survey of dose indices from radiotherapy treatment planning computed tomography scans for adult patients. Phys Med Biol 2018; 63: 185008. doi: https://doi.org/10.1088/1361-6560/aac877

29. Wolthaus JWH, Schneider C, Sonke JJJ, van Herk M, Belderbos JSA, Rossi MMG, et al. Mid-ventilation CT scan construction from four-dimensional respiration-correlated CT scans for radiotherapy planning of lung cancer patients. Int J Radiat Oncol Biol Phys 2006; 65: 1560–71. doi: https://doi.org/10.1016/j.ijrobp.2006.04.031

30. Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman BJ, Senan S. Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis. J Clin Oncol 2010; 28: 5153–9. doi: https://doi.org/10.1200/JCO.2010.30.0731

31. Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol 2016; 17: 1672–82. doi: https://doi.org/10.1016/S1470-2045(16)30532-0

32. Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, et al. Local consolidative therapy improves overall survival compared to maintenance therapy/observation in oligometastatic non-small-cell lung cancer. 2018 ASTRO Annual Meeting. Abstract LBA3. Presented 2018.

33. Beasley M, Brown S, McNair H, Faivre-Finn C, Franks K, Murray L, et al. The advanced radiotherapy network (ART-NET) UK lung stereotactic ablative radiotherapy survey: national provision and a focus on image guidance. Br J Radiol 2019; 92: 20180988.